Mizuho raised the firm’s price target on Pulse Biosciences (PLSE) to $30 from $25 and keeps an Outperform rating on the shares. The firm cites the company’s “strong showing” 2026 AF Symposium for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Study Results
- Pulse Biosciences says nPulse study demonstrates successful treatment
- Pulse Biosciences initiated with an Outperform at Mizuho
- Pulse Biosciences updates investor deck on cardiac pipeline
- Pulse Biosciences Adds Veteran Healthtech Leader to Board